Abstract |
The sera of patients with hemophilia and von Willebrand factor deficiency, collected during clinical trials with virus-inactivated coagulation factor preparations, were retrospectively screened for the presence of antibodies against hepatitis C virus (HCV). Using the anti-HCV c100-3 assay, 10 out of 35 study patients had no HCV antibodies when entering the studies. The samples originally negative for anti-HCV were retested with a second-generation assay: all negative samples except two were positive on retesting. We conclude that the HCV seroprevalence in Swiss hemophiliacs must be of the order of > 90%. These results confirm that the first-generation assay for HCV antibodies is not sensitive enough; to obtain more accurate information on the seroprevalence of hemophiliacs, second-generation tests should be used.
|
Authors | B A Perret, M Senn, P Affentranger, M Poorbeik, J J Burckhardt, A Morell |
Journal | Schweizerische medizinische Wochenschrift
(Schweiz Med Wochenschr)
Vol. 123
Issue 3
Pg. 79-81
(Jan 23 1993)
ISSN: 0036-7672 [Print] Switzerland |
Vernacular Title | Hepatitis-C-Virus-Serostatus der Hämophilen in der Schweiz. |
PMID | 7678942
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Hepatitis Antibodies
- Hepatitis C Antibodies
|
Topics |
- Hemophilia A
(immunology)
- Hepacivirus
(immunology)
- Hepatitis Antibodies
(isolation & purification)
- Hepatitis C Antibodies
- Humans
- Immunologic Techniques
- Retrospective Studies
- von Willebrand Diseases
(immunology)
|